MCID: OPP004
MIFTS: 43

Oppositional Defiant Disorder malady

Categories: Mental diseases

Aliases & Classifications for Oppositional Defiant Disorder

Aliases & Descriptions for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050856
ICD10 33 F91.3

Summaries for Oppositional Defiant Disorder

MalaCards based summary : Oppositional Defiant Disorder is related to autism spectrum disorder and personality disorder, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include eye and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 71 Oppositional defiant disorder (ODD) is defined by the DSM-5 as \"a pattern of angry/irritable mood,... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 29.6 COMT DRD4 SLC6A2 SLC6A3 SLC6A4
2 personality disorder 28.9 COMT DRD2 DRD4 MAOA SLC6A2 SLC6A3
3 conduct disorder 10.7
4 attention deficit-hyperactivity disorder 10.7
5 anxiety disorder 10.2
6 dissociative disorder 10.2 DRD4 MAOA
7 conjunctival pigmentation 10.2 MAOA SLC6A4
8 anodontia 10.2 SLC6A3 SLC6A4
9 sphenoorbital meningioma 10.1 DRD2 DRD4
10 neurogenic bladder 10.1 MAOA SLC6A4
11 intracranial aneurysm 10.1 DRD2 DRD4
12 littre gland carcinoma 10.1 SLC6A2 SLC6A3
13 adult brainstem astrocytoma 10.1 MAOA SLC6A4
14 cholestasis-lymphedema syndrome 10.1 COMT MAOA
15 euthyroid sick syndrome 10.1 DRD2 SLC6A4
16 nephronophthisis 13 10.1 COMT SLC6A4
17 lethal congenital contracture syndrome 1 10.1 COMT MAOA
18 tinea pedis 10.1 MAOA SLC6A3 SLC6A4
19 18p deletion syndrome 10.1 DRD2 DRD4 SLC6A3
20 waardenburg's syndrome 10.0 DRD2 SLC6A4
21 rhinoscleroma 10.0 COMT DRD2
22 kidney pelvis papillary carcinoma 10.0 MAOA SLC6A2 SLC6A4
23 intracranial cavernous angioma 10.0 DRD2 SLC6A3 SLC6A4
24 epithelioid type angiomyolipoma 10.0 SLC6A2 SLC6A3 SLC6A4
25 splenic abscess 10.0 DRD2 SLC6A3 SLC6A4
26 hypoglycemic coma 10.0 MAOA SLC6A4
27 ornithosis 10.0 DRD2 MAOA SLC6A4
28 myopathy, distal, with early respiratory failure, autosomal dominant 10.0 COMT SLC6A3
29 alzheimer disease 17 10.0 DRD4 SLC6A4 TPH2
30 alopecia 10.0 DRD2 DRD4 SLC6A4
31 mastitis 10.0 DRD4 SLC6A3
32 urea cycle disorder 10.0 COMT DRD2
33 chronic eosinophilic pneumonia 9.9 COMT MAOA SLC6A4
34 primary angle-closure glaucoma 9.9 COMT SLC6A4
35 c8 deficiency, type ii 9.9 COMT DRD2 DRD4
36 atrial fibrillation, familial, 10 9.9 MAOA SLC6A4 TPH2
37 lichen disease 9.9 COMT MAOA SLC6A4
38 pythiosis 9.9 DBH MAOA
39 apperceptive agnosia 9.9 COMT DRD2 SLC6A4
40 tic disorder 9.9
41 hematohidrosis 9.9
42 alcohol dependence 9.9
43 bipolar disorder 9.9
44 stuttering 9.9
45 separation anxiety disorder 9.9
46 borderline personality disorder 9.9
47 reading disorder 9.9
48 generalized anxiety disorder 9.9
49 rectosigmoid junction neoplasm 9.9 DRD2 DRD4 SLC6A3 TPH2
50 scoliosis 9.9 DBH DRD2 SLC6A3

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:



Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 homeostasis/metabolism MP:0005376 9.91 COMT DBH DRD2 DRD4 MAOA SLC6A2
3 cardiovascular system MP:0005385 9.87 COMT DBH DRD2 MAOA SLC6A2 SLC6A4
4 integument MP:0010771 9.63 DBH DRD2 SLC6A2 SLC6A3 SLC6A4 TPH2
5 nervous system MP:0003631 9.61 COMT DBH DRD2 DRD4 MAOA SLC6A2
6 taste/olfaction MP:0005394 8.8 DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
5
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
6
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
7
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
8
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
11 Antipsychotic Agents Phase 4,Phase 3,Phase 2
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
13 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3
14 Dopamine Agents Phase 4,Phase 3,Phase 2
15 Dopamine Antagonists Phase 4,Phase 3,Phase 2
16 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2
20
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
21 Serotonin Agents Phase 4,Phase 3,Phase 2
22 Serotonin Antagonists Phase 4,Phase 3,Phase 2
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2
24 Adrenergic Agents Phase 4,Phase 3
25 Adrenergic Agonists Phase 4
26 Adrenergic alpha-2 Receptor Agonists Phase 4
27 Adrenergic alpha-Agonists Phase 4
28 Antihypertensive Agents Phase 4
29 Anticonvulsants Phase 4
30 Antimanic Agents Phase 4
31 GABA Agents Phase 4
32 Atomoxetine Hydrochloride Phase 4,Phase 3
33 Autonomic Agents Phase 4
34 Peripheral Nervous System Agents Phase 4
35 Antiemetics Phase 4
36 Gastrointestinal Agents Phase 4
37 insulin Phase 4
38 Insulin, Globin Zinc Phase 4
39 Serotonin Uptake Inhibitors Phase 4
40
Ethanol Approved Phase 2, Phase 3 64-17-5 702
41 Pharmaceutical Solutions Phase 3,Phase 2
42 Anti-Infective Agents Phase 2, Phase 3
43 Anti-Infective Agents, Local Phase 2, Phase 3
44 Disinfectants Phase 2, Phase 3
45 Phenylethyl Alcohol Phase 2, Phase 3
46
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
47 Quetiapine Fumarate Phase 2 111974-72-2
48 Oxytocics Phase 2
49
Benzocaine Approved 1994-09-7, 94-09-7 2337
50 tannic acid Approved, Nutraceutical

Interventional clinical trials:

(show top 50) (show all 56)
id Name Status NCT ID Phase
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4
2 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4
3 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4
4 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4
5 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4
6 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4
7 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4
8 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4
9 Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Recruiting NCT02638168 Phase 4
10 Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Recruiting NCT02951754 Phase 4
11 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Completed NCT00192023 Phase 3
12 Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Completed NCT00191698 Phase 3
13 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
14 Strongest Families Ontario (Formerly the Family Help Program) Completed NCT01473511 Phase 3
15 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3
16 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3
17 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3
18 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3
19 Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Completed NCT00402857 Phase 3
20 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3
21 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2
22 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
23 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior. Completed NCT00550147 Phase 2
24 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2
25 Treatment of Conduct Problems and Depression Unknown status NCT01267773 Phase 1
26 Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189
27 Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986
28 Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT01330849
29 Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Support Unknown status NCT01660425
30 Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Completed NCT00510120
31 Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Completed NCT00404911
32 Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits Completed NCT01362946
33 On-line Treatment for Conduct Problems Completed NCT01822392
34 Supplements and Social Skills Intervention Study Completed NCT00819429
35 Resources to Enhance the Adjustment of Children (REACH) Completed NCT00820001
36 The Effectiveness of Parent-Child Interaction Therapy (PCIT) Completed NCT01085305
37 School-Based Mental Health Services for Urban Children Completed NCT00612690
38 Brain Changes in Children and Adolescents With Behavioral Problems Completed NCT00104039
39 Correlating Real and Virtual World Behavioral Fluctuations in Adolescence Completed NCT02281825
40 Anger Control Training for Youth With Tourette Syndrome Completed NCT00486551
41 Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges Completed NCT02766101
42 Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) Completed NCT00579267
43 Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions Recruiting NCT02409992
44 Treatment of Children With Peer Related Aggressive Behavior (ScouT) Recruiting NCT02143427
45 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Recruiting NCT02707848
46 Psychological Treatments for Youth With Severe Irritability. Recruiting NCT02531893
47 Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children Recruiting NCT02433145
48 Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention Recruiting NCT02121431
49 Family Groups for Urban Youth With Disruptive Behavior Recruiting NCT02715414
50 Mobile Health Solutions for Behavioral Skill Implementation Through Homework Recruiting NCT01917838

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

39
Eye, Cortex

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 118)
id Title Authors Year
1
Oppositional defiant disorder dimensions: genetic influences and risk for later psychopathology. ( 28059443 )
2017
2
Is emotional dysregulation a risk indicator for auto-aggression behaviors in adolescents with oppositional defiant disorder? ( 27764737 )
2017
3
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
4
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2016
5
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
6
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2016
7
Maltreatment and Emotional and Behavioral Problems in Chinese Children With and Without Oppositional Defiant Disorder: The Mediating Role of the Parent-Child Relationship. ( 26811315 )
2016
8
Innocent or Intentional?: Interpreting Oppositional Defiant Disorder in a Preschool Mental Health Clinic. ( 27761690 )
2016
9
Perceived Parent-Child Relations, Conduct Problems, and Clinical Improvement Following the Treatment of Oppositional Defiant Disorder. ( 27284234 )
2016
10
The role of anxiety in cortisol stress response and cortisol recovery in boys with oppositional defiant disorder/conduct disorder. ( 27521740 )
2016
11
Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children. ( 27443598 )
2016
12
Emotion Socialization in the Context of Risk and Psychopathology: Maternal Emotion Coaching Predicts Better Treatment Outcomes for Emotionally Labile Children with Oppositional Defiant Disorder. ( 26848211 )
2016
13
Child Personality Accounts for Oppositional Defiant Disorder Comorbidity Patterns. ( 27233508 )
2016
14
Oral health status, dental anxiety, and behavior-management problems in children with oppositional defiant disorder. ( 26707341 )
2016
15
Trait and State Variance in Oppositional Defiant Disorder Symptoms: A Multi-Source Investigation With Spanish Children. ( 27148784 )
2016
16
Common Questions About Oppositional Defiant Disorder. ( 27035043 )
2016
17
Preschool Oppositional Defiant Disorder: A Disorder of Negative Affect, Surgency, and Disagreeableness. ( 27768388 )
2016
18
Multiple Levels of Family Factors and Oppositional Defiant Disorder Symptoms Among Chinese Children. ( 27900762 )
2016
19
Emotional Regulation and Executive Function Deficits in Unmedicated Chinese Children with Oppositional Defiant Disorder. ( 27247593 )
2016
20
Emotional Abilities in Children with Oppositional Defiant Disorder (ODD): Impairments in Perspective-Taking and Understanding Mixed Emotions are Associated with High Callous-Unemotional Traits. ( 27100725 )
2016
21
Emotion Regulation Difficulties in Boys with Oppositional Defiant Disorder/Conduct Disorder and the Relation with Comorbid Autism Traits and Attention Deficit Traits. ( 27420110 )
2016
22
Early development of comorbidity between symptoms of attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). ( 26854502 )
2016
23
The Longitudinal Effects of Oppositional Defiant Disorder Symptoms on Academic and Occupational Functioning in the Transition to Young Adulthood. ( 27469319 )
2016
24
The Reciprocal Influence of Callous-Unemotional Traits, Oppositional Defiant Disorder and Parenting Practices in Preschoolers. ( 27013514 )
2016
25
Memory consolidation of socially relevant stimuli during sleep in healthy children and children with attention-deficit/hyperactivity disorder and oppositional defiant disorder: What you can see in their eyes. ( 28049026 )
2016
26
Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis. ( 27282758 )
2016
27
Association of tryptophan hydroxylase-2 polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 27871272 )
2016
28
Predicting Depression and Anxiety from Oppositional Defiant Disorder Symptoms in Elementary School-Age Girls and Boys with Conduct Problems. ( 27209374 )
2016
29
Beyond Symptom Counts for Diagnosing Oppositional Defiant Disorder and Conduct Disorder? ( 25788042 )
2015
30
The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 1: Psychostimulants, Alpha-2 Agonists, and Atomoxetine. ( 25886655 )
2015
31
The Associations Between Pre- and Postnatal Maternal Symptoms of Distress and Preschooler's Symptoms of ADHD, Oppositional Defiant Disorder, Conduct Disorder, and Anxiety. ( 26647350 )
2015
32
Implicit emotion regulation: linking childhood oppositional defiant disorder with adult depression and bipolar disorder? ( 26536579 )
2015
33
Prevalence of Oppositional Defiant Disorder in a sample of Spanish children between six and sixteen years: teacher’s report. ( 26631304 )
2015
34
DISC Predictive Scales (DPS): Factor Structure and Uniform Differential Item Functioning Across Gender and Three Racial/Ethnic Groups for ADHD, Conduct Disorder, and Oppositional Defiant Disorder Symptoms. ( 25774639 )
2015
35
Socioeconomic status and oppositional defiant disorder in preschoolers: parenting practices and executive functioning as mediating variables. ( 26441784 )
2015
36
Neurocognitive Deficits in Attention-Deficit/Hyperactivity Disorder With and Without Comorbid Oppositional Defiant Disorder. ( 26486602 )
2015
37
Oppositional defiant disorder dimensions and subtypes among detained male adolescent offenders. ( 26493948 )
2015
38
Child maltreatment and interpersonal relationship among Chinese children with oppositional defiant disorder. ( 26560234 )
2015
39
The influence of comorbid oppositional defiant disorder on white matter microstructure in attention-deficit/hyperactivity disorder. ( 26507746 )
2015
40
Bifactor Latent Structure of Attention-Deficit/Hyperactivity Disorder (ADHD)/Oppositional Defiant Disorder (ODD) Symptoms and First-Order Latent Structure of Sluggish Cognitive Tempo Symptoms. ( 26502205 )
2015
41
Callous-unemotional traits in a child with attention-deficit/hyperactivity disorder and oppositional defiant disorder: managing medication and expectations. ( 25885014 )
2015
42
Clinical Characteristics of Preschool Children with Oppositional Defiant Disorder and Callous-Unemotional Traits. ( 26418062 )
2015
43
A multidomain cascade model of early childhood risk factors associated with oppositional defiant disorder symptoms in a community sample of 6-year-olds. ( 26646055 )
2015
44
Variability in emotional/behavioral problems in boys with oppositional defiant disorder or conduct disorder: the role of arousal. ( 26608403 )
2015
45
Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. ( 26097819 )
2015
46
Hot and Cool Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. ( 26416095 )
2015
47
Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. ( 25886657 )
2015
48
Subfactors of oppositional defiant disorder: converging evidence from structural and latent class analyses. ( 25907358 )
2015
49
Pharmacological Management of Pediatric Patients with Comorbid Attention-Deficit Hyperactivity Disorder Oppositional Defiant Disorder. ( 26233632 )
2015
50
The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 2: Antipsychotics and Traditional Mood Stabilizers. ( 25886656 )
2015

Variations for Oppositional Defiant Disorder

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 COMT MAOA SLC6A3 SLC6A4
2
Show member pathways
12.39 COMT DRD2 DRD4 MAOA SLC6A3
3 12.26 COMT DBH TPH2
5 11.92 MAOA SLC6A4 TPH2
6 11.86 SLC6A2 SLC6A3 SLC6A4
7
Show member pathways
11.72 DRD2 MAOA SLC6A3
8 11.69 MAOA SLC6A4 TPH2
9
Show member pathways
11.48 COMT DBH MAOA
10
Show member pathways
11.23 COMT SLC6A2 SLC6A4
11
Show member pathways
11.17 DBH TPH2
12 10.91 DBH SLC6A2
13 10.88 MAOA SLC6A4 TPH2
14
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
15
Show member pathways
10.69 COMT MAOA SLC6A3 SLC6A4
16
Show member pathways
10.67 COMT DBH MAOA
17 10.66 COMT MAOA
18
Show member pathways
10.64 COMT MAOA

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.86 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 integral component of plasma membrane GO:0005887 9.55 DRD2 DRD4 SLC6A2 SLC6A3 SLC6A4
3 axon GO:0030424 9.5 COMT DRD2 SLC6A3
4 membrane raft GO:0045121 9.13 SLC6A2 SLC6A3 SLC6A4
5 neuron projection GO:0043005 8.92 SLC6A2 SLC6A3 SLC6A4 TPH2

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 34)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.8 COMT DRD2 SLC6A2 SLC6A3 SLC6A4
2 locomotory behavior GO:0007626 9.7 DBH DRD2 SLC6A3
3 neurotransmitter transport GO:0006836 9.69 SLC6A2 SLC6A3 SLC6A4
4 social behavior GO:0035176 9.66 DRD4 SLC6A4
5 visual learning GO:0008542 9.66 DBH DRD2
6 response to nicotine GO:0035094 9.65 DRD2 SLC6A3
7 response to cocaine GO:0042220 9.65 DRD2 SLC6A3
8 positive regulation of multicellular organism growth GO:0040018 9.65 DRD2 SLC6A3
9 associative learning GO:0008306 9.64 DBH DRD2
10 negative regulation of adenylate cyclase activity GO:0007194 9.64 DRD2 DRD4
11 arachidonic acid secretion GO:0050482 9.63 DRD2 DRD4
12 behavioral response to cocaine GO:0048148 9.63 DRD2 DRD4
13 dopamine receptor signaling pathway GO:0007212 9.62 DRD2 DRD4
14 response to iron ion GO:0010039 9.62 DRD2 SLC6A3
15 neurotransmitter biosynthetic process GO:0042136 9.61 SLC6A3 SLC6A4
16 ammonium transmembrane transport GO:0072488 9.61 SLC6A3 SLC6A4
17 response to amphetamine GO:0001975 9.61 DBH DRD2 DRD4
18 prepulse inhibition GO:0060134 9.6 DRD2 SLC6A3
19 negative regulation of protein secretion GO:0050709 9.59 DRD2 DRD4
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.58 DRD2 DRD4
21 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
22 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.57 DRD2 DRD4
23 catecholamine metabolic process GO:0006584 9.56 COMT MAOA
24 regulation of dopamine metabolic process GO:0042053 9.55 DRD4 SLC6A3
25 adenohypophysis development GO:0021984 9.54 DRD2 SLC6A3
26 response to pain GO:0048265 9.54 COMT DBH SLC6A2
27 behavioral response to ethanol GO:0048149 9.5 DBH DRD2 DRD4
28 fear response GO:0042596 9.49 DBH DRD4
29 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
30 response to histamine GO:0034776 9.46 DRD2 DRD4
31 dopamine metabolic process GO:0042417 9.43 COMT DRD2 DRD4
32 monoamine transport GO:0015844 9.33 SLC6A2 SLC6A3 SLC6A4
33 dopamine uptake involved in synaptic transmission GO:0051583 9.13 SLC6A2 SLC6A3 SLC6A4
34 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.58 SLC6A2 SLC6A3 SLC6A4
2 drug binding GO:0008144 9.5 DRD2 DRD4 SLC6A3
3 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
5 dopamine binding GO:0035240 9.33 DRD2 DRD4 SLC6A3
6 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.13 SLC6A2 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 8.8 SLC6A2 SLC6A3 SLC6A4

Sources for Oppositional Defiant Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....